Table 5. CT findings for 251 patients with HMPV pneumonia without another pathogen, South Korea*.
| Characteristic | Immunocompetent | Solid tumors | SOT | HCT | HM | Steroid use | Total |
|---|---|---|---|---|---|---|---|
| Patients with HMPV pneumonia without another pathogen | 259 | 81 | 36 | 7 | 29 | 41 | 453 |
| Patients who underwent CT scans | 138 | 43 | 26 | 3 | 23 | 18 | 251 |
| Bilateral | 100 (72.5) | 34 (79.1) | 21 (80.8) | 3 (100) | 20 (87.0) | 14 (77.8) | 192 (76) |
| No. involved lobes | 3 (2–6) | 5 (3–6) | 4 (2–5) | 6 (6–6) | 5 (3–6) | 4 (3–5) | 4 (2–6) |
| Macronodule | 67 (49) | 19 (44) | 11 (31) | 1 (33) | 12 (52) | 4 (22) | 114 (45) |
| Patients with centrilobular nodules | 101 (73) | 28 (65) | 17 (47) | 2 (67) | 13 (57) | 13 (72) | 174 (69) |
| Extent of centrilobular nodules | 10 (5–30) | 10 (0–20) | 10 (0–20) | 20 (10–20) | 10 (0–20) | 10 (0–23) | 10 (5–20) |
| Patients with consolidation | 57 (41) | 20 (47) | 13 (50) | 0 | 8 (35) | 9 (50) | 107 (43) |
| Extent of consolidation | 0 (0–10) | 0 (0–15) | 3 (0–10) | 0 (0–0) | 0 (0–10) | 8 (0–20) | 0 (0–10) |
| Patients with ground-glass opacity | 109 (79) | 38 (88) | 21 (81) | 2 (67) | 15 (65) | 14 (78) | 199 (79) |
| Extent of ground-glass opacity | 10 (10–20) | 10 (10–30) | 10 (10–23) | 10 (10–10) | 10 (5–20) | 18 (9–33) | 10 (10–20) |
| Bronchial wall thickening | 121 (88) | 35 (81) | 25 (96) | 3 (100) | 1 (4) | 17 (94) | 222 (88) |
| Bronchiectasis | 17 (12) | 4 (9) | 4 (15) | 1 (33) | 3 (13) | 5 (28) | 34 (14) |
| Cavitation | 1 (0.7) | 0 | 0 | 0 | 0 | 1 (6) | 2 (1) |
| Lymphadenopathy | 40 (29) | 14 (33) | 6 (23) | 0 (0) | 2 (9) | 6 (33) | 68 (27) |
| Pleural effusion | 24 (17) | 15 (35) | 7 (27) | 1 (33) | 5 (22) | 4 (22) | 56 (22) |
*Values are no. (%) or median (interquartile range) unless otherwise indicated. CT, computed tomography; HCT, hematologic stem cell transplantation; HM, hematologic malignancy; LRD, lower respiratory tract disease; SOT, solid organ transplants; URI, upper respiratory tract infection.